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Abstract: The analgesic effect of tramadol (TMD) results from the monoaminergic effect of its two enantiomers, (+)-TMD
and ())-TMD as well as its opioid metabolite (+)-O-desmethyl-tramadol (M1). P-glycoprotein (P-gp) might be of
importance in the analgesic and tolerability profile variability of TMD. Our study investigated the involvement of P-gp
in the transepithelial transport of (+)-TMD, ())-TMD and M1, using a Caco-2 cell monolayer model. The bidirectional
transport of racemic TMD and M1 (1–100 lM) across the monolayers was investigated at two pH conditions (pH 6.8/7.4
and 7.4/7.4) in the presence and absence of P-gp inhibitor cyclosporine A (10 lM) and assessed with the more potent and
specific P-gp inhibitor GF120918 (4 lM). Analytical quantification was performed by liquid chromatography coupled to
the fluorescence detector. A net secretion of (+)-TMD, ())-TMD and M1 was observed when a pH gradient was applied
(TR: Papp(B ) A)/Papp(A ) B): 1.8–2.7; P < 0.05). However, the bidirectional transport of all compounds was equal in the
non-gradient system. In the presence of P-gp inhibitors, a slight but significant increase of secretory flux was observed (up
to 26%; P < 0.05) at both pH conditions. In conclusion, (+)-TMD, ())-TMD and M1 are not P-gp substrates. However,
proton-based efflux pumps may be involved in limiting the gastrointestinal absorption of TMD enantiomers as well as
enhancing TMD enantiomers and M1 renal excretion. A possible involvement of uptake carriers in the transepithelial
transport of TMD enantiomers and M1 is suggested.
Tramadol hydrochloride (TMD) is a centrally acting analgesic
structurally related to codeine and morphine [1]. Experi-
mental and clinical studies have demonstrated the analgesic
efficacy and tolerability of TMD in acute and chronic
nociceptive and neuropathic pain of both malignant and
non-malignant origin [2–4]. TMD is mainly metabolised
by O- and N-demethylation and by conjugation reactions,
forming glucuronides and sulfates. The O-demethylation of
TMD to its opioid active moiety O-desmethyl-tramadol (M1)
is catalysed by cytochrome P450 (CYP) 2D6, whereas N-
demethylation to N-desmethyl-TMD (M2) is catalysed by
CYP2B6 and CYP3A4 (fig. 1) [5,6]. Both enantiomers of
TMD, (+)-TMD and ())-TMD, as well as its major metabolite
M1 contribute to its analgesic activity via different mechanisms.
M1 acts mainly as a l opioid agonist (Ki: 0.0034 lmol/l)
whereas (+)-TMD and ())-TMD inhibit serotonin and nore-
pinephrine reuptake, respectively (Ki: 0.53 and 0.43 lmol/l),
thus enhancing the inhibitory effect on pain transmission in
the spinal cord [7,8]. The complementary and synergistic actions
of the three compounds confer a unique pharmacodynamic
profile to TMD [9].
However, wide variability in the pharmacokinetic/
pharmacodynamic properties of TMD has been shown.
This has been partly ascribed to CYP2D6 polymorphism, as
the l opioid TMD effect is mainly M1-dependent [10–13].
Stereoselective O- and N-demethylation, as well as renal
elimination of TMD, have also been well-characterized
[14,15].
P-glycoprotein (P-gp/MDR1/ABCB1) is a broad-spectrum
efflux transporter that limits substrate xenobiotic exposure in
the body, thus playing a crucial role in drug pharmacokinetics
and biodisposition [16]. It has been shown to stereo-
selectively transport numerous drug enantiomers in several
in vitro and in vivo studies [17–20]. The potential stereo-
selective transport of TMD enantiomers by an ABC efflux
drug transporter as well as a preferential transport of TMD
and M1 have not yet been investigated. These may play
non-negligible roles in the biodisposition of each compound
and, therefore, the final expected central analgesic effect of
the drug racemate and its active opioid metabolite M1.
Several opioid analgesics have been shown to be substrates
as well as inhibitors of P-gp in studies using the in vitro
Caco-2 monolayer model [21–23].
The present study assessed whether the two enantiomers
of TMD and its metabolite M1 were subject to an active
efflux transport across biological membranes, focusing mainly
ontheeffluxtransporterP-gp.
Materials and Methods
Materials. Caco-2 cells (TC7 clone) were kindly provided by Martin
Rumbo, PhD (ISREC, Swiss Institute for Experimental Cancer
Research, Lausanne, Switzerland). 32-(N-morpholino)ethane-sulfonic
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Germany), penicillin–streptomycin from Sigma Aldrich GmbH
(Steinheim, Germany), non-essential amino acids from Biochrom AG
(Berlin, Germany) and all other cell culture reagents from Gibco BRL
(Scotland, England). [
3H]-mannitol and Pico-Fluor 15 medium were
purchased from Perkin Elmer Life Sciences (Zaventem, Belgium). TMD
and O-desmethyl-TMD, cyclosporine A and [N-(4-[2-(1,2,3,4-tetrahydro-
6,7 dimethoxy-2-isoquinolinyl) ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-
oxo-4-acridine carboxamide] (GF120918) were kindly provided by
Gr nenthal GmbH (Stolberg, Germany), Novartis Pharma (Basel,
Switzerland) and GlaxoSmithKline (Stevenage, UK), respectively.
Cell culture. Caco-2 cells (TC7 clone) were used at passages 40–55.
Cells were cultured in Dulbecco's modified Eagle's medium (DMEM
Glutamax, Gibco BRL) supplemented by 10% foetal bovine serum
(FBS, Gibco BRL), 1% non-essential amino acids (NEA, Biochrom
AG) and 100 U/ml penicillin and 100 lg/ml streptomycin (Sigma
Aldrich) at 37  in a humidified atmosphere with 5% CO2.A t
85–95% confluency, Caco-2 cells were treated with 0.25% trypsine-
EDTA (Gibco BRL) and seeded at a density of 65,000 cells/cm
2 on
polycarbonate membranes of Transwells (12 mm diameter, 1.13 cm
2,
0.4 lm pore size, 12-well plates; Costar, Cambridge, MA), previously
equilibrated for 1 hr. Medium was changed the day after seeding
and every other day thereafter (apical volume (A): 0.5 ml, basolateral
volume (B): 1.5 ml). Monolayers were used for transport studies
20–21 days post-seeding to allow full maturation of the cells,
including P-gp expression and appropriate tight junctions.
Measurement of transepithelial electrical resistance (TEER). TEER
was checked every 5 days during the 21-day monolayers maturation.
Prior to bidirectional transport studies, medium was removed from
both apical and basolateral chambers and monolayers were rinsed
three times with the transport buffer Hank's balanced salt solution
(HBSS) supplemented with 25 mM N-(2-hydroxylethyl)piperazine-
N¢-2ethane-sulfonic acid (HEPES) (Gibco BRL) and pH-adjusted
to 7.4 with 0.5 M NaOH. Cells were equilibrated in the same buffer for
1 hr and the integrity of each monolayer was checked by measuring
its transepithelial electrical resistance (TEER) with a Millicell-ERS
ohmmeter (Millipore Corp., Bedfort, MA). Resistance was also checked
immediately after the transport experiments.
Transmission electron microscopy and Western blotting of P-gp.
Transmission electron microscopy and Western blotting of P-gp
were performed in our earlier study in the context of the validation
of our Caco-2 cell model. Histological examination showed a con-
tinuous, differentiated cell monolayer presenting microvillus on the
apical cell surface, interdigitations, numerous desmosomes (maculae
adherents) and tight junctions. Western blot analysis revealed a
C219 antibody-reactive band of 170 kD corresponding to P-gp
expression [24].
Transport studies. The bidirectional transport of the two enantiomers
of TMD and M1 (1–100 lM) was investigated at pH 6.8/7.4 and
7.4/7.4 in the presence and absence of cyclosporine A, at respectively
1–100 and 4–400 times the plasma concentrations (Cmax) that
produce a clearcut analgesic effect after a 100 mg dose of TMD
in vivo [25]. The pH gradient condition (6.8/7.4) was used to examine
whether pH-mediated efflux mechanisms are involved in TMD and
M1 transport across pH gradients that exist in intestinal and kidney
transport [26,27]. The bidirectiona lt r a n s p o r to fa l lm o l e c u l e sw a s
assessed at the lowest concentration (1 lM) with GF120918 at
physiological pH (7.4/7.4) to confirm P-gp interaction with the
drugs tested. Indeed, GF120918 does not inhibit the multi-resistance
proteins (MRPs) [28]. It may inhibit the breast cancer resistance
protein (BCRP) but this transporter is expressed in very low
extent in Caco-2 cells [29].
pH 6.8/7.4 condition: After measurement of TEERs, HBSS buffer
was removed from each chamber. Apical to basolateral (A-B)
transport was initiated by replacing basolateral (B) buffer with
1.5 ml of fresh HBSS supplemented with 25 mM HEPES (Gibco
BRL) and pH-adjusted to 7.4 with NaOH 0.5 M, and replacing
apical (A) buffer with 0.5 ml of the drug solution in HBSS supple-
mented with 10 mM MES (AppliChem GmbH), pH-adjusted to 6.8
with 0.5 M NaOH. Into another insert, B–A transport was initiated
by replacing (A) buffer with 0.5 ml of fresh HBSS/MES pH 6.8
and (B) buffer with the drug solution in HBSS/HEPES (1.5 ml).
For the P-gp inhibition studies, the inhibitor was present in both
chambers. Cyclosporine A and GF120918 were used at 10 and
4 lM, respectively. Samples (150 llf o rT M Da n d1 0 0llf o rM 1 )
were removed from each receiver chamber at various times (30, 60,
90, 120 and 180 min) and replaced with buffer to maintain constant
volumes. The 3-hr transport studies were performed at a constant
agitation rate (50 rpm) using a circular shaker (type SSM1, Stuart
 )
in an incubator (37 ,5 %C O 2 and humidified atmosphere).
pH 7.4/7.4 condition: As described for the pH 6.8/7.4 condition
except that (A) and (B) buffers and drug solutions were made with
HBSS supplemented with 25 mM HEPES pH 7.4.
After the transport studies, all aliquots were stored at –20  until
analysis.
Paracellular transport of [
3H]-mannitol. Apical to basolateral
permeability (A-B) of [
3H]-mannitol, a radio-labelled paracellular
marker (activity: 0.5 lCi/ml), was measured over 3 hr to monitor
the integrity of monolayers tight junctions. Samples taken from
the basolateral side (100 ll) at various times were counted in a
Pico-Fluor 15 medium using a liquid scintillation counter (Packard
Instruments).
Analytical method. Analysis of (+)-TMD, ())-TMD and M1 was
performed by liquid chromatography coupled to the fluorescence
detector. A stereo-selective method was applied for (+)-TMD and
())-TMD determination using a Chiral AGP column (100 · 4.0 mm),
as previously described [30] with slight modifications. The mobile
phase consisted of a mixture of acetonitrile and phosphate buffer,
100 mM pH 7.0 (2/98) and was delivered at 0.9 ml/min. M1 analysis
was performed using a MN phenyl column (70 · 4.0 mm). The
mobile phase consisted of a mixture of acetonitrile and orthopho-
sphoric acid, 50 mM (15/85) pH 3.0, and was delivered at 0.8 ml/
min. For both TMD and M1, fluorescence was measured with emission
and excitation wavelengths set at 275 and 308 nm, respectively. In all
Fig. 1. Major in vivo metabolic pathways for tramadol.
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Method performances in terms of reproducibility, repeatability and
linearity were assessed before analysis (data not shown). Rhodamine
123 analysis was performed as previously described [24].
In all cases, the samples consisted of aliquots removed from the
receiver chambers (drug solution in the aqueous buffer HBSS). No
additional treatment was needed. No extraction was required and
the samples were directly injected into the HPLC system without
need for an internal standard.
Calculations. TEER was calculated from the following equation
[31]:
TEER ¼ð TEERmono   TEERblankÞ A
where the TEERmono is the cell monolayer and polycarbonate
porous membrane resistance, TEERblank the polycarbonate porous
membrane resistance and A the polycarbonate porous membrane
surface area (1.13 cm
2).
Apical to basolateral (Papp (A – B)) and basolateral to apical
(Papp (B – A)) apparent permeability coefficients were calculated
according to Artursson [32] using the following equation:
Pappðcm=sec:Þ¼ð dQ=dtÞ=ðA   C0   60Þ
Where dQ/dt(lg/min)isthepermeabilityrateofthedrug,calculated
fromthe regression lineof the timepoints ofsampling, A isthe surface
area of the monolayer (cm
3)a n dC0 the initial drug concentration in
thedonorchamber(lg/l).
Karlsson[33] suggested the involvementofa drugeffluxtransporter
in the investigated Caco-2 cells if the efflux ratio (TR ¼ Papp(B – A)/
Papp(A – B)) is >2 and if a decreased secretory transport rate
(Papp(B – A)) is observed in the presence of an inhibitor of this
transporter. For a compound with an efflux ratio of 1.5–2.0, a
positive effect of the inhibitor confirm the implication of the efflux
transporter[34].
Statistics. The Unpaired Student test was used for statistical com-
parison of the transport rates in each direction, the transport rate
in the presence and absence of the P-gp inhibitor for a particular
direction, the transport efflux ratios in relation to pH conditions
and the transport efflux ratio difference in relation to P-gp inhibitor
addition (Xlstat version 5.0). A P value of <0.05 was considered
significant.
Results
Integrity of Caco-2 cell monolayers.
Transepithelial electrical resistance (TEER). Caco-2 cell
monolayers with TEER values between 250 and 350 XÆcm
2
were used in the study. Measurements conducted after the
experiments displayed similar values and confirmed the
integrity of the monolayers during all of the experiments.
No tendency towards an effect on TEERwas observed under
the various experimental conditions (pH, substrates
and inhibitors).
Paracellular transport of [
3H]-mannitol. The transport rate
of radio-labelled [
3H]-mannitol was <1% per hr, showing
functional tight junctions. As for TEER, no tendency towards
an effect on [
3H]-mannitol permeability was observed under
the various experimental conditions (pH, substrates and
inhibitors).
P-glycoprotein activity.
Transepithelial transport of P-gp probe. The P-gp probe
rhodamine 123 (5 lM) [35] was representative of a good
activity of P-gp in our Caco-2 cell monolayers. Indeed,
our results indicate active transport of rhodamine 123 in
the basolateral-to-apical direction (secretion) that exceeds
the level of transport in the apical-to-basolateral direction
(absorption). Furthermore, in the presence of the P-gp
inhibitor cyclosporine A (10 lM), we observed a marked
increase of the absorptive flux (Papp(A–B): 4.8 € 0.2 versus
7.8 € 0.3; P < 0.05) and decrease of the secretory one
(Papp(B–A): 6.4 € 0.7 versus 1.2 € 0.3; P < 0.05) (fig. 2).
Transepithelial transport of (+)-TMD, (–)-TMD and M1.
Transepithelial transport of (+)-TMD and ())-TMD. Under
the pH 6.8/7.4 condition, a significant efflux ratio (TR) of
the two enantiomers was observed, with a 1.9 to 2.7-fold
higher transepithelial transport from the basolateral to
apical side (B–A) than from the apical to basolateral side
(A–B). A–B transport was not affected by cyclosporine A,
however, although not statistically significant, a trend towards
a decrease of the influx (A–B) (up to 13%) was observed. A
statistically significant increase of the efflux (B–A) (up to
18%, at all concentrations except 100 lM), and thus of the
efflux ratio, was observed in the presence of cyclosporine A
(P < 0.05) (table 1, fig. 3).
At physiological pH, the differential transport was nearly
abolished (0.9 < TR < 1.2). As for the pH gradient con-
dition, the A–B transport was not significantly affected
Fig. 2. Transepithelial transport of rhodamine 123 across Caco-2
cell monolayers and the effect of cyclosporine A.
Rhodamine 123 (5 lM) was added to the apical side (open columns) or
the basolateral side (solid columns) of the monolayers in the presence
(+cyclosporine) or absence (control) of 10 lMc y c l o s p o r i n eAa tp H
6.8/7.4. Data are the mean € SD of 3 experiments. *P < 0.05.
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nificant increase of the efflux (B–A) (up to 10%), with a
slight increase of the efflux ratio, was observed in the
presence of cyclosporine A, although this was less pro-
nounced than under the pH gradient condition (P < 0.05)
(table 1, fig. 3).
At physiological pH, the A–B transport of (+)-TMD and
())-TMD was not modulated by GF120918 at the lowest
concentration (1 lM), however, a statistically significant
increase of the efflux (B–A) (17%) was observed (P < 0.05)
(table 2).
Transepithelial transport of M1. Underthe pH 6.8/7.4condi-
tion, a significant efflux ratio was observed with a 1.8 to
2.3-fold higher transepithelial transport from the basolateral
to apical side (B–A) than from the apical to basolateral side
(A–B).The A–B transport wasnotaffectedbycyclosporineA,
except for a statistically significant decrease observed at
1 lM. A statistically significant increase of the efflux (B–A)
(up to 26%) at all concentrations, and thus of the efflux ratio,
was observed in the presence of cyclosporine A (P < 0.05)
(table1,fig.4).
At physiological pH, the differential transport was nearly
abolished (0.9 < TR < 1.1). The A–B transport was not affected
by cyclosporine A. An overall statistically significant increase
of the efflux (B–A) (up to 14%), although less pronounced
than at the pH gradient condition, was observed (P < 0.05)
(table1,fig.4).
At physiological pH, the B–A transport of M1 was not
modulated by GF120918 at the lowest concentration (1 lM),
however, a statistically significant decrease of the influx
(A–B) (20%) was observed (P < 0.05) (table 2).
Discussion
Our study demonstrates that the two enantiomers of TMD
as well as its active opioid metabolite M1 are not P-gp sub-
strates. Indeed, a significant secretory transport of the three
Table 1.
Apparent permeability coefficients, Papp (cm/sec.), of (+)-TMD, ())-TMD and M1 in the presence and absence of cyclosporine A, at pH 6.8/7.4
and pH 7.4/7.4.
Papp (A – B) Papp (B – A) Papp (A – B) Papp (B – A)
(cm/sec.) (10
)6) (cm/sec.) (10
)6)
Drug concentration € P-gp inhibitor pH 6.8/7.4 Efflux ratio (TR) pH 7.4/7.4 Efflux ratio (TR)
(+)-TMD
1 lM 14.1 € 0.8 31.1 € 0.8* 2.2 (efflux) 28.1 € 0.5 31.5 € 1.3 1.1 (no net flux)
‡
+1 0lM Cyclosporine A 15.6 € 1.2 34.0 € 0.7
† 2.1 26.2 € 3.4 34.6 € 0.8
† 1.3
10 lM 11.0 € 0.7 26.9 € 0.5* 2.4 (efflux) 33.5 € 1.4 38.8 € 1.6 1.1 (no net flux)
‡
+1 0lM Cyclosporine A 9.6 € 1.1 28.8 € 0.6
† 3.0
§ 30.2 € 2.1 39.4 € 0.8 1.3
50 lM 10.3 € 0.5 25.6 € 2.3* 2.4 (efflux) 52.5 € 1.1 65.3 € 1.0* 1.2 (no net flux)
‡
+1 0lM Cyclosporine A 9.3 € 0.6 31.2 € 0.7
† 3.3
§ 49.9 € 2.5 69.6 € 0.7
† 1.3
§
100 lM 22.6 € 1.9 60.9 € 1.3* 2.6 (efflux) 41.7 € 3.6 66.9 € 0.4* 1.6 (no net flux)
‡
+1 0lM Cyclosporine A 21.7 € 1.9 61.7 € 2.0 2.8 39.1 € 1.5 68.2 € 0.9 1.7
())-TMD
1 lM 16.7 € 0.5 32.2 € 0.5* 1.9 (efflux) 31.0 € 1.9 30.8 € 1.8 0.9 (no net flux)
‡
+1 0lM Cyclosporine A 18.7 € 1.1
† 36.0 € 0.3
† 1.9 29.2 € 1.1 34.2 € 0.8
† 1.1
§
10 lM 11.0 € 0.5 26.9 € 0.5* 2.4 (efflux) 33.5 € 2.2 37.2 € 0.4 1.1 (no net flux)
‡
+1 0lM Cyclosporine A 10.2 € 1.0 28.9 € 0.5
† 2.8
§ 29.9 € 1.5 39.0 € 0.6
† 1.3
§
50 lM 10.3 € 0.5 25.4 € 2.3* 2.4 (efflux) 52.9 € 1.0 63.4 € 3.8 1.1 (no net flux)
‡
+1 0lM Cyclosporine A 9.4 € 0.6 31.2 € 0.8
† 3.3
§ 50.9 € 1.7 68.9 € 0.4 1.3
100 lM 22.4 € 1.8 61.3 € 1.0* 2.7 (efflux) 41.1 € 2.9 64.3 € 3.4* 1.5 (no net flux)
‡
+1 0lM Cyclosporine A 21.7 € 2.0 62.5 € 2.0 2.8 37.3 € 1.0 67.7 € 1.5 1.8
M1
1 lM 8.3 € 0.3 16.4 € 0.5* 1.9 (efflux) 18.0 € 0.9 17.7 € 0.0 0.9 (no net flux)
‡
+1 0lM Cyclosporine A 7.3 € 0.2
† 21.2 € 0.6
† 2.9 18.2 € 0.5 19.3 € 0.5
† 1.0
§
10 lM 6.5 € 0.3 12.0 € 0.8* 1.8 (efflux) 12.9 € 1.1 14.2 € 0.8 1.1 (no net flux)
‡
+1 0lM Cyclosporine A 6.8 € 0.3 15.1 € 0.5
† 2.2
§ 12.8 € 0.9 15.0 € 0.3 1.1
50 lM 5.8 € 1.0 13.7 € 0.3* 2.3 (efflux) 15.2 € 0.4 17.4 € 0.6 1.1 (no net flux)
‡
+1 0lM Cyclosporine A 5.3 € 0.5 16.1 € 0.7
† 3.0
§ 15.4 € 1.0 20.1 € 2.4 1.3
100 lM 6.7 € 0.4 15.2 € 0.0* 2.2 (efflux) 12.2 € 0.9 13.7 € 0.1 1.1 (no net flux)
‡
+1 0lM Cyclosporine A 6.8 € 0.7 20.6 € 0.3
† 3.0
§ 11.7 € 1.1 15.2 € 0.7
† 1.2
The efflux ratio shown here is the net basolateral to apical flux direction (TR ¼ Papp(B–A)/Papp(A–B)).
*P < 0.05. Significant difference in transport direction.
†P < 0.05. Significance of the inhibitor effect for a given transport direction.
‡P < 0.05. Significant difference in transport efflux ratios in relation to pH conditions.
§P < 0.05. Significant difference in transport efflux ratios in relation to inhibitor addition for a given pH condition.
Values are the mean € SD of three experiments.
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(TR: 1.8–2.7; P < 0.05), suggesting the involvement of an
efflux transporter. However, the observed polarised trans-
port was abolished at physiological pH. Furthermore, no
effect of the first generation and non-specific P-gp inhibitor
cyclosporine A and the more potent and specific inhibitor
third generation GF120918, in the way of an increase of the
absorptive flux (Papp(A–B)) and a decrease of the secretory
flux (Papp(B–A)), at both pH conditions was observed. Our
P-gp positive control rhodamine 123 showed a polarised
transport across the Caco-2 monolayers in the way of a net
active secretion as well as a 80% decrease of its secretory
transport and 38% increase of the absorptive one in the
presence of the P-gp inhibitor cyclosporine A. Consequently,
TMD enantiomers and M1 are not P-gp substrates, at
respectively 1–100 and 4–400 times the maximal plasma
concentrations (Cmax) that produce a clear-cut analgesic
effect after a single oral dose of 100 mg TMD racemate [25].
Fig. 3. Transepithelial transport of (+)-tramadol and ())-tramadol across Caco-2 cell monolayers, the effect of cyclosporine A and the
influence of pH conditions.
(+)-tramadol (I) and ())-tramadol (II) (10 lM) were added to the apical side (open columns) or the basolateral side (solid columns) of the
monolayers in the presence (+cyclosporine) or absence (control) of 10 lM cyclosporine A at pH 6.8/7.4 (A) and pH 7.4/7.4 (B). Data are the
mean € SD of three experiments. *P < 0.05.
Table 2.
Apparent permeability coefficients, Papp (cm/sec.), of (+)-TMD,
())-TMD and M1 in the presence and absence of GF120918 at
pH 7.4/7.4.
Drug
concentration € P-gp
inhibitor
Papp (A–B) Papp (B–A)
(cm/sec.) (10
)6)
pH 7.4/7.4 Efflux ratio (TR)
(+)-TMD
1 lM 42.6 € 6.2 52.3 € 2.9 1.2 (no net flux)
+4lM GF120918 45.8 € 3.7 60.6 € 2.1* 1.3
())-TMD
1 lM 43.8 € 5.8 51.1 € 1.9 1.1 (no net flux)
+4lM GF120918 44.8 € 4.0 61.3 € 2.8* 1.3
M1
1 lM 16.9 € 1.3 16.5 € 0.7 0.9 (no net flux)
+4lM GF120918 13.5 € 1.3* 16.2 € 0.5 1.2
Theeffluxratioshownhereisthenetbasolateraltoapicalfluxdirection
(TR ¼ Papp(B–A)/Papp(A–B)).
*P < 0.05. Significance of the inhibitor effect for a given transport
direction.
Values are the mean € SD of three experiments.
Fig. 4. Transepithelial transport of O-desmethyl-tramadol across Caco-2
cell monolayers, the effect of cyclosporine A and the influence of pH
conditions.
O-desmethyl-tramadol (10 lM) was added to the apical side (open
columns) or the basolateral side (solid columns) of the monolayers in
the presence (+cyclosporine) or absence (control) of 10 lM cyclosporine A
at pH 6.8/7.4 (A) and pH 7.4/7.4 (B). Data are the mean € SD of
threeexperiments.*P<0.05.
TRAMADOL AND O-DESMETHYL-TRAMADOL INTERACTION 203
  2009 The Authors
Journal compilation   2009 Nordic Pharmacological Society. Basic & Clinical Pharmacology & Toxicology, 105, 199–206These experimental results are in accordance with the
results of pharmacogenetic clinical studies evaluating the
role of P-gp in TMD kinetics. In fact, although a role of
the P-gp polymorphism C3435T in the pharmacokinetics
of TMD has been suggested in a small clinical trial involving
patients with selected CYP2D6 and MDR1 polymorphisms,
no statistically significant difference in kinetics was found
between the 3435CC, CT and TT groups, independently of
CYP2D6 polymorphisms, nor was influence of the G2677T/A
polymorphism observed. A significant difference between
the pooled CC + CT and TT patients was found only in the
CYP2D6 poor metabolizers, and concerned the Cmax
parameter only. M1 pharmacokinetics was found to be
MDR1 polymorphism-independent [36].
The Caco-2 cell model is one of the most commonly
used high throughput and cost-effective in vitro models for
evaluating permeability and P-gp interaction potential
of drug candidates. This model is recommended by the
Food and Drug Administration (FDA) for the identification
of substrates, inhibitors and inducers of P-gp through
bidirectional transport studies [37,38]. The calibration of the
model with appropriate reference probes and a thorough
understanding of the rationale underlying the caveats
associated with this model allow the results to be put in the
proper perspective [24,39]. The Caco-2 cell monolayers are
moreover a good model for pH-gradient transport studies
for the following reasons: (i) the monolayers remain intact at
apical pH values that cover the entire physiological range
of the intestinal tract; (ii) they lack a protective mucus
layer, which means that the pH at the cell surface rapidly
equilibrates and becomes equal to the bulk pH of the
applied buffer solution [40].
In our study, (+)TMD, ())-TMD and M1 permeability in
the apical-to-basolateral (A–B) direction (absorptive flux)
decreased approximately by 50% when apical pH was reduced
from pH 7.4 to 6.8, resulting in a significant efflux ratio of the
drugs (TR: Papp(B–A)/Papp(A–B): 1.8–2.7; P < 0.05). TMD
and M1 are weak bases. This pH dependency of TMD and
M1 absorptive flux is not explained by the passive diffusion
of the unionised form according to the pH-partition theory.
Indeed, the pKa of TMD is 9.4 and pH values in our study
are among 2 and 2.4 units below its pKa. Hence, 100%
of TMD is in the ionised form at both pH 6.8 and 7.4. M1
pKa is unknown but it is expected to be close to that of
TMD. Therefore, the polarised transport of (+)-TMD,
())-TMD and M1 observed under a pH gradient is probably
related to the contribution of specific efflux transport
system(s). The overall effect of the P-gp inhibitors used in our
study on the transepithelial transport of the two enantiomers
of TMD and M1 was a statistically significant increase of
the secretory flux (up to 18% and 26%, respectively), with
an increase of the efflux ratio (TR), at both pH conditions. A
higher increase of the secretory flux of TMD enantiomers
was observed with GF120918 at physiological pH as com-
pared with cyclosporine A (17% versus 10%). Moreover, a
significant decrease of the absorptive flux of M1 (approxi-
mately 20%) was observed in the presence of GF120918
while no effect was observed with cyclosporine A. This
apparent paradoxical effect of P-gp inhibitors suggests
the involvement of uptake drug transporter(s) in the
transmembranetransportofTMDenantiomersandM1.
The gastrointestinal tract and the kidney provide a unique
environment of cellular transport due to the presence of
proton-based efflux pumps such as the Na
+–H
+ and the
organic cation/H
+ exchangers [26,27]. The Na
+–H
+ antiporter
has been characterized in Caco-2 cells [41] and studies using
the Caco-2 cell model showed an active secretory transport
of weak bases such as celiprolol, loperamide, zolmitriptan,
diphenydramine and amphetamine derivatives by proton-
based efflux pumps [33,42–45]. H
+ antiport systems might
therefore be involved in the limitation of the gastrointestinal
absorption of TMD as well as renal excretion of TMD and
M1. The use of specific inhibitors such as amiloride, or
cimetidine could help confirming this hypothesis [33,42–45].
Apart from efflux drug transporters, Caco-2 cells express
several uptake transporters. The most relevant are the
organic anion transporting polypeptide OATP2B1/SLCO2B1,
the peptide transporter PEPT1/SLC15A1, the organic
cation/carnitine OCNT2/SLC22A5 as well as the mono-
carboxylic acid transporters MCT1/SLC16A1 and MCT5/
SLC16A5 and the human peptide transporter HPT1/
CDH17 [46,47]. PEPT1 is inhibited by cyclosporine A [48].
Moreover, it has been shown to transport endogenous
opioid peptides and consequently might be relevant in the
oral bioavailability of synthetic opioids [49].
TMD and M1 cross easily the blood–brain barrier [25].
They appear to cross the cellular membrane efficiently
and to accumulate in tissues, and these pharmacokinetic
properties are in concordance with our study results. Indeed,
a comparative study of Caco-2 monolayer permeability
and human drug absorption suggests that compounds with
Papp >1 0· 10
)6 cm/sec. can be classified as well-absorbed
compounds (70–100%) [50]. Since TMD (pKa: 9.4) and
M1 are almost 100% protonated at both pH conditions
tested, a passive diffusion mechanism may not fully explain
TMD and M1 high tissue distribution. The involvement
of uptake transporters seems therefore relevant in this case.
More specific in vitro models are required to support our
observations.
In conclusion, (+)-TMD, ())-TMD and the major analgesic
metabolite O-desmethyl-TMD are not P-gp substrates.
However, proton-based efflux pumps may be involved in
limiting the gastrointestinal absorption of TMD enantiomers
and as well as enhancing TMD enantiomers and M1 renal
excretion. Moreover, our investigations suggest the possible
involvement of uptake carriers in their transepithelial trans-
port across biological membranes. The hypothesis advanced,
which might be of importance in the prediction of clinically
significant drug interactions, needs to be investigated.
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